|
|
News Breaks | | | | February 4, 2013 | | 09:07 EDT |  | BCLI | BrainStorm says first patient begins treatment in Phase IIa trial for ALS
BrainStorm Cell Therapeutics announced that the first patient began treatment in the company’s Phase IIa dose-escalating clinical trial for ALS. The trial, which will evaluate the safety and preliminary efficacy of BrainStorm’s NurOwn stem cell therapy candidate, is being conducted at the Hadassah Medical Center in Jerusalem. In the Phase IIa trial, three groups of four patients will receive combined intramuscular and intrathecal administration of NurOwn cells, in increasing doses. The first cohort of four patients is expected to complete treatment by the end of April 2013. The trial participants will be monitored for three to six months following transplantation. | |
|
News For BCLI From The Last 14 Days Check below for free stories on BCLI the last two weeks. |
|
|
| There are no results for BCLI |
|
|
|
|
|
|
